215 related articles for article (PubMed ID: 21760896)
1. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
[TBL] [Abstract][Full Text] [Related]
2. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
3. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
4. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
5. In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.
Goubard A; Clavel F; Mammano F; Labrosse B
Antivir Ther; 2009; 14(4):597-602. PubMed ID: 19578246
[TBL] [Abstract][Full Text] [Related]
6. Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.
Leung MY; Cohen FS
Biophys J; 2011 Apr; 100(8):1960-8. PubMed ID: 21504732
[TBL] [Abstract][Full Text] [Related]
7. Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Yuan C; Wang JY; Zhao HJ; Li Y; Li D; Ling H; Zhuang M
Retrovirology; 2019 Dec; 16(1):36. PubMed ID: 31796053
[TBL] [Abstract][Full Text] [Related]
8. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
Xu L; Pozniak A; Wildfire A; Stanfield-Oakley SA; Mosier SM; Ratcliffe D; Workman J; Joall A; Myers R; Smit E; Cane PA; Greenberg ML; Pillay D
Antimicrob Agents Chemother; 2005 Mar; 49(3):1113-9. PubMed ID: 15728911
[TBL] [Abstract][Full Text] [Related]
9. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
[TBL] [Abstract][Full Text] [Related]
10. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
Lu J; Sista P; Giguel F; Greenberg M; Kuritzkes DR
J Virol; 2004 May; 78(9):4628-37. PubMed ID: 15078945
[TBL] [Abstract][Full Text] [Related]
11. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
[TBL] [Abstract][Full Text] [Related]
12. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
[TBL] [Abstract][Full Text] [Related]
13. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
Dwyer JJ; Wilson KL; Martin K; Seedorff JE; Hasan A; Medinas RJ; Davison DK; Feese MD; Richter HT; Kim H; Matthews TJ; Delmedico MK
Protein Sci; 2008 Apr; 17(4):633-43. PubMed ID: 18359857
[TBL] [Abstract][Full Text] [Related]
14. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
Bai X; Wilson KL; Seedorff JE; Ahrens D; Green J; Davison DK; Jin L; Stanfield-Oakley SA; Mosier SM; Melby TE; Cammack N; Wang Z; Greenberg ML; Dwyer JJ
Biochemistry; 2008 Jun; 47(25):6662-70. PubMed ID: 18507398
[TBL] [Abstract][Full Text] [Related]
15. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Wei X; Decker JM; Liu H; Zhang Z; Arani RB; Kilby JM; Saag MS; Wu X; Shaw GM; Kappes JC
Antimicrob Agents Chemother; 2002 Jun; 46(6):1896-905. PubMed ID: 12019106
[TBL] [Abstract][Full Text] [Related]
16. The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.
Cunyat F; Marfil S; García E; Svicher V; Pérez-Alvárez N; Curriu M; Perno CF; Clotet B; Blanco J; Cabrera C
Retrovirology; 2012 Feb; 9():15. PubMed ID: 22333046
[TBL] [Abstract][Full Text] [Related]
17. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
18. Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.
Chinnadurai R; Münch J; Kirchhoff F
AIDS; 2005 Sep; 19(13):1401-5. PubMed ID: 16103771
[TBL] [Abstract][Full Text] [Related]
19. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
[TBL] [Abstract][Full Text] [Related]
20. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy.
Teixeira C; de Sá-Filho D; Alkmim W; Janini LM; Diaz RS; Komninakis S
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):307-11. PubMed ID: 20334566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
